The Huabei Pharmaceutical Factory, established in the 1950s and having made a great contribution to the country’s medical industry, once hesitated to press forward in the process of the transformation from the planne...The Huabei Pharmaceutical Factory, established in the 1950s and having made a great contribution to the country’s medical industry, once hesitated to press forward in the process of the transformation from the planned economy to the market economy. However, the situation took a turn for the better in 1993. It set an alltime record in its industrial output value, sales income and foreign exchange earnings through exports, taxes, labour productivity and energy consumption that year. The output value, sales income and profit and tax returns increased 16.22%, 24.51% and 13.32% respectively over the previous year. In 1994 the output value, sales income, profit and tax returns stood at RMB1.2 billion, RMB1.27 billion, RMB250 million and RMB 115 million, a rise of 32.85%, 60.63%, 61.25% and 55.98% over 1993 respectively.展开更多
Acta Pharmaceutica Sinica B(APSB) has been selected for coverage in the Science Citation Index Expanded(SCIE), online at the Web of Knowledge. Coverage of this title in SCIE begins with Vol. 5 No. 1, 2015. The 2018 Im...Acta Pharmaceutica Sinica B(APSB) has been selected for coverage in the Science Citation Index Expanded(SCIE), online at the Web of Knowledge. Coverage of this title in SCIE begins with Vol. 5 No. 1, 2015. The 2018 Impact Factor is released as 5.808, ranking 17/267 in the category Pharmacology and Pharmacy.展开更多
Acta Pharmaceutica Sinica B (APSB) has been selected for coverage in the Science Citation Index Expanded (SCIE), online at the Web of Knowledge. Coverage of this title in SCIE begins with Vol. 5 No. 1, 2015. The 2017 ...Acta Pharmaceutica Sinica B (APSB) has been selected for coverage in the Science Citation Index Expanded (SCIE), online at the Web of Knowledge. Coverage of this title in SCIE begins with Vol. 5 No. 1, 2015. The 2017 Impact Factor is released as6.014, ranking 16/261 in the category Pharmacology and Pharmacy.展开更多
Acta Pharmaceutica Sinica B(APSB)has been selected for coverage in the Science Citation Index Expanded(SCIE),online at the Web of Knowledge.Coverage of this title in SCIE begins with Vol.5 No.1,2015.The 2018 Impact Fa...Acta Pharmaceutica Sinica B(APSB)has been selected for coverage in the Science Citation Index Expanded(SCIE),online at the Web of Knowledge.Coverage of this title in SCIE begins with Vol.5 No.1,2015.The 2018 Impact Factor is released as 5.808,ranking 17/267 in the category Pharmacology and Pharmacy.展开更多
Acta Pharmaceutica Sinica B(APSB)has been selected for coverage in the Science Citation Index Expanded(SCIE),online at the Web of Knowledge.Coverage of this title in SCIE begins with Vol.5 No.1,2015.The 2018 Impact Fa...Acta Pharmaceutica Sinica B(APSB)has been selected for coverage in the Science Citation Index Expanded(SCIE),online at the Web of Knowledge.Coverage of this title in SCIE begins with Vol.5 No.1,2015.The 2018 Impact Factor is released as 5.808, ranking 17/267 in the category Pharmacology and Pharmacy.展开更多
1. HIF-1α pathway: role, regulation and intervention for cancer therapy Acta Pharm Sin B 2015; 5: 378-389(Georgina N. Masoud, Wei Li) 2. Mechanisms of resistance to EGFR tyrosine kinase inhibitors Acta Pharm Sin B 20...1. HIF-1α pathway: role, regulation and intervention for cancer therapy Acta Pharm Sin B 2015; 5: 378-389(Georgina N. Masoud, Wei Li) 2. Mechanisms of resistance to EGFR tyrosine kinase inhibitors Acta Pharm Sin B 2015; 5: 390-401(Lihua Huang, Liwu Fu) 3. Cancer metastases: challenges and opportunities Acta Pharm Sin B 2015; 5: 402-418(Xiangming Guan)展开更多
1. HIF-1α pathway: role, regulation and intervention for cancer therapy Acta Pharm Sin B 2015;5:378-389 (Georgina N. Masoud, Wei Li).2. Mechanisms of resistance to EGFR tyrosine kinase inhibitors Acta Pharm Sin B 201...1. HIF-1α pathway: role, regulation and intervention for cancer therapy Acta Pharm Sin B 2015;5:378-389 (Georgina N. Masoud, Wei Li).2. Mechanisms of resistance to EGFR tyrosine kinase inhibitors Acta Pharm Sin B 2015;5: 390-401(Lihua Huang, Liwu Fu).3. Cancer metastases: challenges and opportunities Acta Pharm Sin B 2015;5: 402-418 (XiangmingGuan).4. Insoluble drug delivery strategies: review of recent advances and business prospects Acta PharmSin B 2015;5: 442-453 (Sandeep Kalepu, VijaykumarNekkanti).展开更多
Acta Pharmaceutica Sinica B(APSB)has been selected for coverage in the Science Citation Index Expanded(SCIE),online at the Web of Knowledge.Coverage of this title in SCIE begins with Vol.5 No.1,2015.The 2018 Impact Fa...Acta Pharmaceutica Sinica B(APSB)has been selected for coverage in the Science Citation Index Expanded(SCIE),online at the Web of Knowledge.Coverage of this title in SCIE begins with Vol.5 No.1,2015.The 2018 Impact Factor is released as 5.808,ranking 17/267 in the category Pharmacology and Pharmacy.展开更多
Acta Pharmaceutica Sinica B(APSB)has been selected for coverage in the Science Citation Index Expanded(SCIE),online at the Web of Knowledge.Coverage of this title in SCIE begins with Vol.5 No.1,2015.The 2018 Impact Fa...Acta Pharmaceutica Sinica B(APSB)has been selected for coverage in the Science Citation Index Expanded(SCIE),online at the Web of Knowledge.Coverage of this title in SCIE begins with Vol.5 No.1,2015.The 2018 Impact Factor is released as 5.808,ranking 17/267 in the category Pharmacology and Pharmacy.展开更多
1.Targeting calcium signaling in cancer therapy Acta Pharm Sin B 2017;1:3-172.An updated overview on the development of new photosensitizers for anticancer photodynamic therapy Acta Pharm Sin B 2018;2:137-1463.Mesopor...1.Targeting calcium signaling in cancer therapy Acta Pharm Sin B 2017;1:3-172.An updated overview on the development of new photosensitizers for anticancer photodynamic therapy Acta Pharm Sin B 2018;2:137-1463.Mesoporous silica nanoparticles for drug and gene delivery Acta Pharm Sin B 2018;2:165-1774.Regulation of multidrug resistance by microRNAs in anti-cancer therapy Acta Pharm Sin B 2017;1:38-515.Nanotechnology-based strategies for treatment of ocular disease Acta Pharm Sin B 2017;3:281-2916.展开更多
Acta Pharmaceutica Sinica B(APSB)has been accepted for inclusion in Pub Med Central(PMC),the world’s largest and most-used biomedical literature database.Currently,papers published from Volume 4 onwards can be search...Acta Pharmaceutica Sinica B(APSB)has been accepted for inclusion in Pub Med Central(PMC),the world’s largest and most-used biomedical literature database.Currently,papers published from Volume 4 onwards can be searched in Pub Med.PMC,launched in February 2000,is a freely-available database of full-text articles on life sciences and biomedical topics.Journals accepted to展开更多
Acta Pharmaceutica Sinica B(APSB)has been accepted for inclusion in PubMed Central(PMC),the world’s largest and most-used biomedical literature database.Currently,papers published from Volume 4 onwards can be searche...Acta Pharmaceutica Sinica B(APSB)has been accepted for inclusion in PubMed Central(PMC),the world’s largest and most-used biomedical literature database.Currently,papers published from Volume 4 onwards can be searched in PubMed.展开更多
Acta Pharmaceutica Sinica B(APSB)has been accepted for inclusion in PubMed Central(PMC),the world’s largest and most-used biomedical literature database.Currently,papers published from Volume 4 onwards can be searche...Acta Pharmaceutica Sinica B(APSB)has been accepted for inclusion in PubMed Central(PMC),the world’s largest and most-used biomedical literature database.Currently,papers published from Volume 4 onwards can be searched in PubMed.展开更多
Acta Pharmaceutica Sinica B (APSB)has been accepted for inclusion in Pub Med Central(PMC),the world’s largest and most-used biomedical literature database.Currently,papers published from Volume 4 onwards can
Acta Pharmaceutica Sinica B(APSB)has been accepted for inclusion in Pub Med Central(PMC),the world’s largest and most-used biomedical literature database.Currently,papers published from Volume 4 onwards can be search...Acta Pharmaceutica Sinica B(APSB)has been accepted for inclusion in Pub Med Central(PMC),the world’s largest and most-used biomedical literature database.Currently,papers published from Volume 4 onwards can be searched in Pub Med.PMC,launched in February 2000,is a freely-available database of展开更多
Acta Pharmaceutica Sinica B(APSB)has been accepted for inclusion in Pub Med Central(PMC),the world’s largest and most-used biomedical literature database.Currently,papers published from Volume 4 onwards can be search...Acta Pharmaceutica Sinica B(APSB)has been accepted for inclusion in Pub Med Central(PMC),the world’s largest and most-used biomedical literature database.Currently,papers published from Volume 4 onwards can be searched in Pub Med.PMC,launched in February 2000,is a freely-available database of full-text articles on life sciences and biomedical topics.Journals accepted to展开更多
Acta Pharmaceutica Sinica B(APSB)has been accepted for inclusion in PubMed Central(PMC),the world’s largest and most-used biomedical literature database.Currently,papers published from Volume 4 onwards can be searche...Acta Pharmaceutica Sinica B(APSB)has been accepted for inclusion in PubMed Central(PMC),the world’s largest and most-used biomedical literature database.Currently,papers published from Volume 4 onwards can be searched in PubMed.PMC,launched in February 2000,is a freely-available database of full-text articles on life sciences and biomedical topics.Journals accepted to展开更多
文摘The Huabei Pharmaceutical Factory, established in the 1950s and having made a great contribution to the country’s medical industry, once hesitated to press forward in the process of the transformation from the planned economy to the market economy. However, the situation took a turn for the better in 1993. It set an alltime record in its industrial output value, sales income and foreign exchange earnings through exports, taxes, labour productivity and energy consumption that year. The output value, sales income and profit and tax returns increased 16.22%, 24.51% and 13.32% respectively over the previous year. In 1994 the output value, sales income, profit and tax returns stood at RMB1.2 billion, RMB1.27 billion, RMB250 million and RMB 115 million, a rise of 32.85%, 60.63%, 61.25% and 55.98% over 1993 respectively.
文摘Acta Pharmaceutica Sinica B(APSB) has been selected for coverage in the Science Citation Index Expanded(SCIE), online at the Web of Knowledge. Coverage of this title in SCIE begins with Vol. 5 No. 1, 2015. The 2018 Impact Factor is released as 5.808, ranking 17/267 in the category Pharmacology and Pharmacy.
文摘Acta Pharmaceutica Sinica B (APSB) has been selected for coverage in the Science Citation Index Expanded (SCIE), online at the Web of Knowledge. Coverage of this title in SCIE begins with Vol. 5 No. 1, 2015. The 2017 Impact Factor is released as6.014, ranking 16/261 in the category Pharmacology and Pharmacy.
文摘Acta Pharmaceutica Sinica B(APSB)has been selected for coverage in the Science Citation Index Expanded(SCIE),online at the Web of Knowledge.Coverage of this title in SCIE begins with Vol.5 No.1,2015.The 2018 Impact Factor is released as 5.808,ranking 17/267 in the category Pharmacology and Pharmacy.
文摘Acta Pharmaceutica Sinica B(APSB)has been selected for coverage in the Science Citation Index Expanded(SCIE),online at the Web of Knowledge.Coverage of this title in SCIE begins with Vol.5 No.1,2015.The 2018 Impact Factor is released as 5.808, ranking 17/267 in the category Pharmacology and Pharmacy.
文摘1. HIF-1α pathway: role, regulation and intervention for cancer therapy Acta Pharm Sin B 2015; 5: 378-389(Georgina N. Masoud, Wei Li) 2. Mechanisms of resistance to EGFR tyrosine kinase inhibitors Acta Pharm Sin B 2015; 5: 390-401(Lihua Huang, Liwu Fu) 3. Cancer metastases: challenges and opportunities Acta Pharm Sin B 2015; 5: 402-418(Xiangming Guan)
文摘1. HIF-1α pathway: role, regulation and intervention for cancer therapy Acta Pharm Sin B 2015;5:378-389 (Georgina N. Masoud, Wei Li).2. Mechanisms of resistance to EGFR tyrosine kinase inhibitors Acta Pharm Sin B 2015;5: 390-401(Lihua Huang, Liwu Fu).3. Cancer metastases: challenges and opportunities Acta Pharm Sin B 2015;5: 402-418 (XiangmingGuan).4. Insoluble drug delivery strategies: review of recent advances and business prospects Acta PharmSin B 2015;5: 442-453 (Sandeep Kalepu, VijaykumarNekkanti).
文摘Acta Pharmaceutica Sinica B(APSB)has been selected for coverage in the Science Citation Index Expanded(SCIE),online at the Web of Knowledge.Coverage of this title in SCIE begins with Vol.5 No.1,2015.The 2018 Impact Factor is released as 5.808,ranking 17/267 in the category Pharmacology and Pharmacy.
文摘Acta Pharmaceutica Sinica B(APSB)has been selected for coverage in the Science Citation Index Expanded(SCIE),online at the Web of Knowledge.Coverage of this title in SCIE begins with Vol.5 No.1,2015.The 2018 Impact Factor is released as 5.808,ranking 17/267 in the category Pharmacology and Pharmacy.
文摘1.Targeting calcium signaling in cancer therapy Acta Pharm Sin B 2017;1:3-172.An updated overview on the development of new photosensitizers for anticancer photodynamic therapy Acta Pharm Sin B 2018;2:137-1463.Mesoporous silica nanoparticles for drug and gene delivery Acta Pharm Sin B 2018;2:165-1774.Regulation of multidrug resistance by microRNAs in anti-cancer therapy Acta Pharm Sin B 2017;1:38-515.Nanotechnology-based strategies for treatment of ocular disease Acta Pharm Sin B 2017;3:281-2916.
文摘Acta Pharmaceutica Sinica B(APSB)has been accepted for inclusion in Pub Med Central(PMC),the world’s largest and most-used biomedical literature database.Currently,papers published from Volume 4 onwards can be searched in Pub Med.PMC,launched in February 2000,is a freely-available database of full-text articles on life sciences and biomedical topics.Journals accepted to
文摘Acta Pharmaceutica Sinica B(APSB)has been accepted for inclusion in PubMed Central(PMC),the world’s largest and most-used biomedical literature database.Currently,papers published from Volume 4 onwards can be searched in PubMed.
文摘Acta Pharmaceutica Sinica B(APSB)has been accepted for inclusion in PubMed Central(PMC),the world’s largest and most-used biomedical literature database.Currently,papers published from Volume 4 onwards can be searched in PubMed.
文摘Acta Pharmaceutica Sinica B (APSB)has been accepted for inclusion in Pub Med Central(PMC),the world’s largest and most-used biomedical literature database.Currently,papers published from Volume 4 onwards can
文摘Acta Pharmaceutica Sinica B(APSB)has been accepted for inclusion in Pub Med Central(PMC),the world’s largest and most-used biomedical literature database.Currently,papers published from Volume 4 onwards can be searched in Pub Med.PMC,launched in February 2000,is a freely-available database of
文摘Acta Pharmaceutica Sinica B(APSB)has been accepted for inclusion in Pub Med Central(PMC),the world’s largest and most-used biomedical literature database.Currently,papers published from Volume 4 onwards can be searched in Pub Med.PMC,launched in February 2000,is a freely-available database of full-text articles on life sciences and biomedical topics.Journals accepted to
文摘Acta Pharmaceutica Sinica B(APSB)has been accepted for inclusion in PubMed Central(PMC),the world’s largest and most-used biomedical literature database.Currently,papers published from Volume 4 onwards can be searched in PubMed.PMC,launched in February 2000,is a freely-available database of full-text articles on life sciences and biomedical topics.Journals accepted to
